Abstract:Background: Hepatic inflammatory and fibrotic lesions promote the development of cirrhosir and hepatocellular carcinoma in patients with chronic Hepatitis 8 (CHB). Farly recognition of hepatic histopathological changes and timely initiation of antivical therapy can delay or even reverse disease progression. Objectives: This study aimed to analyze non invasive diagnostic indicators associated inch different inflammation grades, fibrosis stages, and Hepatios degrees in CHB patients, and their outcomes after antiviral therapy Methods: A total of si CHB patients treated at the Third People's Hospital of Shenzhen from January December 2019 were selected for inflammation grading (G) and fibrous staging (5) based on liver puncture examination results. The patients were further dirnded into mild, moderate, and severe chronic Hepatitis groups. Correlation analysis was conducted via Spearman. The diagnostic performance of the relevant indexes for inflammation grading, bibrosi staging, and Hepatios degree grading was evaluated using receiver operator characteristics (ROC) The performance of different ROC curves was further compared using the DeLong rest. The effects of of antiviral drugs on patients with different liver hutopathological degrees were comparatively analyzed after 24, 48, 72, and 95 weeks. Results: Data analysis at baseline showed that 86.81% (79 of 91) of all patients were male. Additionally, about 61.54% (16 of 26), 30.77% (8 of 26), 85.19% (23 of 27), and 62.96% (17 of 27) of patients with normal ALT had G >= 2, G >= 3, S >= 2, and S >= 3, respectively inflammation grade, fibrosis stage, and Hepatitis degree were positively correlated with portal vein internal diameter, spleen thickness. LN, GPR, FIB-4, and 5 index, and negatively correlated with PLT (P<0.05). The area under the curve (AUC) of the ROC assessed multifactorial combinations PSUPTL, PSWPAHPCL, and PSWPHCL for predicting the risk of developing G3 inflammation, 5:3 fibrosis, and moderate to severe Hepatitis in patients with CHB were 0.806, 0.843, and 0.778, respectively. The diagnostic accuracies were higher than some of these factors applied indindually and some commonly used serological markers. HBV DNA levels were significantly lower in different Hepatitis groups after 24 werks of antiviral therapy than before treatment (P<0.05). Furthermore, the ALT normalization rate and HBV DNA clearance rate were slightly higher in the moderate and severe groups than in the mild group alter 48 werks of treatment (P>0.05). The serum liepatitis B envelope antigen (HBeAg) level was nguficantly lower in the severe group than in the mild group after 72 weeks of antiviral therapy (H7.043, P=0.030). Although only the HBeAg serologic conversion rate was significantly different at 96 weeks among the three groups (chi(2) = 12389,P=0.002), (BeAg negative and the serologic conversion rates higher in the severe group at each time point than in the mild and moderate groups Conclusions: Multiple non invasive indicators are strongly associated with different degrees of liver histopathology in patients with chronic HBV infection. Therefore, PSBPTL, PSWPAHPCI, and PSWPHCL can be used to predict the risk of developing Gas inflammation, 53 fibrosis, and moderate to severe Hepatitis in these pacients, respectively. Moreover, short term anuviral therapy has a more pronounced effect on patients with severe Hepatitis by improving hepatic inflammation and inhibiting viral replication.

Associated Factors for Liver Fibrosis and Histological Activity Index in Treatment-Naïve HBeAg-Positive Chronic Hepatitis B Infection: Insights from a Retrospective Analysis

Predictors of Inflammatory Activity in Treatment-Naive Hepatitis B E-Antigen-negative Patients with Chronic Hepatitis B Infection

Serum alkaline phosphatase levels as a simple and useful test in screening for significant fibrosis in treatment-naive patients with hepatitis B e-antigen negative chronic hepatitis B.

Non-ALT Biomarkers for Markedly Abnormal Liver Histology among Chinese Persistently Normal Alanine Aminotransferase-Chronic Hepatitis B Patients.

Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods

Establishment and Validation of a Simple Noninvasive Model to Predict Significant Liver Fibrosis in Patients with Chronic Hepatitis B

A Noninvasive Score to Predict Liver Fibrosis in HBeAg-Positive Hepatitis B Patients with Normal or Minimally Elevated Alanine Aminotransferase Levels.

Title : Interpretation of liver stiffness measurement based approach for the monitoring of hepatitis B patients with antiviral therapy : a 2-year prospective study Running head : Liver stiffness for liver fibrosis monitoring Authors :

Determination of Serum Fibrosis Indexes in Patients with Chronic Hepatitis and Its Significance

A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection

Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection

Hepatitis B core-related antigen serum levels are associated with significant liver fibrosis in treatment-naive chronic HBV infection patients

Noninvasive serum markers for predicting significant liver histopathology in HBeAg-negative chronic HBV-infected patients with normal alanine aminotransferase

Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters.

Predictors of liver fibrosis changes assessed by paired liver biopsies in chronic hepatitis C patients treated with direct-acting antivirals

FibroScan Predicts Liver Fibrosis Progression in Chronic HBV Infection Patients with No Clear Indication for Antiviral Therapy: A Retrospective Cohort Study

Non-invasive Diagnostic Indicators and Antiviral Treatment Efficacy in CHB Patients with Different Liver Histopathological Degrees

Angiopoietin-like protein as a novel marker for liver fibrosis in chronic hepatitis B patients with normal to minimally raised ALT

Prediction of Significant Fibrosis in HBeAg-positive Patients with Chronic Hepatitis B by a Noninvasive Model

The Prediction and Validation of Liver Fibrosis by a Noninvasive Model and Validation in Patients with Chronic Hepatitis B

Serum Markers for Predicting Advanced Fibrosis in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.